Trials / Completed
CompletedNCT01611974
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or solid organ transplants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maribavir | Tablet for oral administration |
Timeline
- Start date
- 2012-07-17
- Primary completion
- 2014-12-05
- Completion
- 2014-12-05
- First posted
- 2012-06-05
- Last updated
- 2021-06-02
- Results posted
- 2015-12-17
Locations
32 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01611974. Inclusion in this directory is not an endorsement.